Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.
Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.
Celgene and Kyn Therapeutics enter a licensing agreement to develop Kyn’s immuno-oncology pipeline for investigative therapies after Celgene was acquired by BMS.
Lonza Pharma & Biotech established itself in Israel, with the opening of a collaborative hub aiming to advance manufacturing technology for cell and gene therapy commercialization.
Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.
LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
The 280,000-square-foot facility will be built in Burlington, Massachusetts and will include a customer collaboration laboratory and training center, in addition to office space.
